NCT06630325 2026-01-07
A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer
OHSU Knight Cancer Institute
Phase 2 Active not recruiting
Clinical Trials
20 trialsNCT04683965 2022-08-02
Pemetrexed and TAS-102 in Combination With Bevacizumab in Refractory Colorectal Cancer
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Unknown
NCT03843853 2022-07-25
Pemetrexed and S-1 in Combination With Bevacizumab in Refractory Colorectal Cancer
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Withdrawn
NCT02588781 2022-06-15
Pemetrexed Alone as Salvage Treatment in Metastatic Colorectal Cancer Patients Who Were Failed After Standard Chemotherapy: A Phase II Single Arm Prospective Study
Samsung Medical Center
Phase 2 Unknown
NCT03086538 2022-06-15
Pemetrexed Plus Tarceva as Salvage Treatment in EGFR Overexpressed Metastatic Colorectal Cancer Patients Who Were Failed After Standard Chemotherapy
Samsung Medical Center
Phase 2 Completed
NCT03110484 2022-06-15
Pemetrexed in Combination With Erlotinib as a Salvage Treatment in Patients With Metastatic Biliary Tract Cancer (BTC) Who Failed Gemcitabine Containing Chemotherapy: A Phase II Single Arm Prospective Study
Samsung Medical Center
Phase 2 Unknown
NCT02723578 2020-01-13
Pemetrexed and Erlotinib for Metastatic Colorectal Cancer
Yonsei University
Phase 2 Completed
NCT01953419 2016-07-28
Phase II Study of Pemetrexed in Advanced or Recurrent Gastric Cancer After Chemotherapy
Sun Yat-sen University
Phase 2 Completed
NCT02296671 2016-03-08
Personalized Therapy for Esophagogastric Cancer Using Thymidylate Synthase Genetic Markers
Washington University School of Medicine
Phase 2 Withdrawn
NCT00383266 2016-01-11
A Phase II Study of Pemetrexed and Carboplatin in the Treatment of Esophageal Cancer
Washington University School of Medicine
Phase 2 Terminated
NCT00864513 2015-12-08
Study of Pemetrexed for Second-Line Pancreas Cancer
Georgetown University
Phase 2 Terminated
NCT01909830 2015-06-19
Gemcitabine in Combination With Pemetrexed Long Term Infusion in the Treatment of Pretreated Metastatic Colorectal Cancer Patients
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Phase 2 Completed
NCT01109615 2012-04-19
PG
Vejle Hospital
Phase 2 Terminated
NCT00191984 2011-01-05
A Study of the Combination of Pemetrexed and Irinotecan Every Two Weeks in Metastatic Colorectal Cancer
Eli Lilly and Company
Phase 2 Completed
NCT00415168 2010-08-17
Pemetrexed Plus Cisplatin as First-Line Treatment in Stage IV or Recurrence of Gastric Cancer
Eli Lilly and Company
Phase 2 Completed
NCT00330915 2009-07-21
A Study of Pemetrexed and Folic Acid Given Before Surgery (Neoadjuvant Treatment) to Patients With Rectal Cancer.
Eli Lilly and Company
Phase 2 Completed
NCT00191412 2007-11-20
A Study of Pemetrexed in the Treatment of Patients With Advanced Metastatic Cancer of the Liver
Eli Lilly and Company
Phase 2 Completed
NCT00490373 2007-06-22
Trial of Pemetrexed for Patients With Pancreatic Cancer Which Cannot be Treated With Surgery or is Metastatic
Eli Lilly and Company
Phase 2 Completed
NCT00190801 2007-01-26
Phase 2 Study on Use of a Combination of Pemetrexed in Patients With Advanced Gastric Carcinoma
Eli Lilly and Company
Phase 2 Completed
NCT00034619 2006-07-19
A Phase 2 Trial of ALIMTA (LY231514, Pemetrexed) Plus Oxaliplatin Administered Every 21 Days for First-Line Treatment of Patients With Advanced Colorectal Cancer.
Eli Lilly and Company
Phase 2 Completed